Physician profile
Mandy Moreno
NPI 1225491053
$3,943.56
in general payments reported to CMS, 2019-2025
27 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,659 · 2022: $645 · 2023: $909 · 2024: $323 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,578 · Education: $61.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.98 |
| Education | $61.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,304.40 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $448.30 | 2021-2025 | Breztri, Airsupra |
| Mayne Pharma Commercial LLC | $412.48 | 2021 | |
| Novo Nordisk INC | $352.30 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $151.89 | 2021-2023 | Resolute Onyx |
| Amgen INC. | $151.04 | 2021-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $142.82 | 2021-2023 | Mounjaro |
| Corcept Therapeutics | $137.54 | 2023 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $85.63 | 2021-2022 | |
| Exact Sciences Corporation | $75.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $74.88 | 2022 | |
| Allergan, INC. | $73.15 | 2021 | |
| Abbott Laboratories | $64.98 | 2022 | |
| Nestle Healthcare Nutrition INC. | $64.58 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $61.98 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $61.95 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.13 | 2021-2024 | |
| Daiichi Sankyo INC. | $38.86 | 2021 | |
| Pfizer INC. | $37.15 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $32.99 | 2023 | Ajovy, Austedo Xr |
| Edwards Lifesciences Corporation | $19.99 | 2022 | |
| Boston Scientific Corporation | $17.62 | 2025 | Wavewriter Alpha Prime 16 |
| Sanofi Pasteur INC. | $15.83 | 2024 | |
| Axsome Therapeutics, INC. | $15.57 | 2024 | Auvelity |
| Actelion Pharmaceuticals US, INC. | $14.60 | 2024 | Opsumit |
| Dexcom, INC. | $14.03 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.